Sun Pharma shares closed over 1% lower at ₹1,931 on BSE following the announcement of its US drug pricing deal, as reported by The Times of India. The stock was among the top losers in the Nifty Pharma index, which declined 1.62% to 26,745.20 points during the intraday session. The decline came after a 3.4% gain in the previous session and snapped a three-day winning run during which the stock had risen about 4.5%. The broader market was also trading lower, with the Sensex down 83.64 points at 76,873.63 and the Nifty 50 falling 44.15 points to 24,036.25 at 9:17 am. According to The Economic Times, the selling pressure in the pharma sector emerged due to Sun Pharma's latest announcement around the company's US drug pricing deal, which seeks to deliver affordable medicines for millions of American patients.
India's largest drugmaker Sun Pharmaceuticals Ltd. has officially signed an agreement with the US government to prioritise access to affordable medicines for American patients, as reported by Mint. As part of the agreement signed on August 31, 2026, Sun Pharma will extend 'Most Favoured Nation' (MFN) pricing to state Medicaid programmes and commit to MFN pricing for future innovative medicine launches in the US market. The agreement recognises Sun Pharma's investment in the US by avoiding tariffs on innovative pharmaceutical products for more than two years, the company said in a regulatory filing on Tuesday. Sun Pharma did not disclose further terms of the deal, terming them as "confidential." According to CNBC TV18, the nine companies that signed the pricing deal on Monday have committed to invest $19.6 billion in US manufacturing over the near-term. Sun Pharma is also part of the list of companies which have agreed to donate Active Pharmaceutical Ingredients for key products to the government's strategic reserves of those ingredients.
The latest agreements have significantly expanded the Trump administration's Most Favoured Nation program, bringing the total number of pharmaceutical manufacturers with MFN deals to 26 companies covering 89% of the branded drug market. As reported by ET Now, the nine companies included in the latest agreements are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Teva Pharmaceuticals, UCB, and Sun Pharma. The White House announced that these agreements will provide every state Medicaid programme with access to MFN drug prices on products made by the nine companies, resulting in billions of dollars in savings for Americans. The latest additions join the existing list of companies including Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Gilead Sciences, Merck, Novartis, Sanofi, Johnson & Johnson, AbbVie, and Regeneron. The administration has already reached deals with 17 major pharmaceutical companies as part of its "most favoured nation" policy, with the first MFN agreement announced with Pfizer on September 30, 2025.
The pricing commitments could potentially weigh on realisations from medicines covered by the agreement, although the financial impact cannot yet be quantified as Sun Pharma did not disclose details such as the products covered, applicable pricing benchmarks or the extent of its affected sales. The White House estimates that the total savings from President Trump's MFN deals could reach $600 billion over the next decade, significantly higher than the previous administration projection of $64.3 billion in federal and state spending over the next decade. The Council of Economic Advisers has provided this updated estimate, reflecting the expanded scope of the program. The administration's TrumpRx.gov platform, launched on February 5, 2026, has already saved patients more than $700 million on medicines since its launch, demonstrating the immediate impact of these pricing initiatives. The deals build on the administration's successful negotiations with major pharmaceutical companies, with companies agreeing to reduce prices for certain medicines to levels comparable with those in other developed nations.
For Sun Pharma, the US represents a critical market with 27% of its global revenue generated from the region, making it the company's largest market for innovative medicines. As reported by Mint, "The United States is a key area of investment and expansion for Sun Pharma across clinical development, sales and marketing, and both API and finished products manufacturing," said Rick Ascroft, North America CEO, Sun Pharma, who represented the company at the White House. The company has been expanding its footprint in the region, with its global innovative medicines portfolio spanning dermatology, ophthalmology and onco-dermatology, now accounting for about 22% of company sales. The company's exposure to the US is also set to increase following its definitive agreement earlier this year to acquire Organon & Co at an enterprise value of $11.75 billion. According to The Times of India, analysts said sales of Sun Pharma's innovative drugs in US are around $1 billion, and are expected to increase to about $3 billion, following the Organon acquisition. Despite Tuesday's decline, Sun Pharma shares have gained about 15% so far in 2026, substantially outperforming the Nifty 50, which is down nearly 8% over the same period. The drugmaker had a market capitalisation of more than ₹4.76 lakh crore based on Monday's closing price.
